Tharimmune Inc

Change company Symbol lookup

Select an option...

THAR Tharimmune Inc

FATH Fathom Digital Manufacturing Corp

PAYX Paychex Inc

WAVD Wavedancer Inc

RNXT RenovoRx Inc

GBNY Generations Bancorp NY Inc

POL Polished.Com Inc

MDGS Medigus Ltd

GTH Genetron Holdings Ltd

NIO NIO Inc

Go

Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The Company uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company's pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.